
The use of zzso to treat chronic cancer pain has been hampered by its short elimination zzso which zzso administration every 4 zzso This study compared the clinical efficacy and safety of a novel zzso zzso with that of zzso in the treatment of cancer zzso 

In a zzso crossover study, 44 patients with stable cancer pain were zzso to zzso zzso or zzso zzso each given every 12 hours for 7 zzso zzso intensity, zzso and sedation were assessed by patients four times daily, and breakthrough analgesia was zzso 

Thirty-one patients completed the study (18 women, 13 zzso mean age, 56 zzso 3 zzso and received a final zzso zzso dose of 124 zzso 22 zzso per day and a final zzso zzso dose of 30 zzso 6 zzso per zzso There were no significant differences between treatments in overall Visual zzso zzso zzso pain intensity zzso 28 zzso 4 zzso zzso 31 zzso 4 zzso zzso pain intensity zzso zzso zzso zzso zzso zzso zzso daily rescue zzso consumption zzso zzso zzso zzso zzso zzso zzso sedation scores (24 zzso 4 zzso zzso 18 zzso 3 zzso zzso scores (15 zzso 3 zzso zzso 13 zzso 3 zzso or patient zzso Two patients experienced hallucinations on zzso zzso but none did while receiving zzso zzso 

zzso zzso demonstrated excellent zzso zzso zzso zzso and safety as compared with zzso zzso and represents an important new therapeutic option for cancer pain zzso 

